We are live on ! Find out more
BLACR

Bellevue Life Sciences Acquisition Corp. Rights
BLACR

Delisted

BLACR was delisted on the 14th of February, 2025.

Back to rankings

30 hedge funds and large institutions have $562K invested in Bellevue Life Sciences Acquisition Corp. Rights in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less funds holding

Funds holding: 31 → 30 (-1)

30% less capital invested

Capital invested by funds: $798K → $562K (-$236K)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
30
Holders Change
-1
Holders Change %
-3.23%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
+$34.1K
2
SCM
Shaolin Capital Management
Florida
+$10.1K
3
Citadel Advisors
Citadel Advisors
Florida
+$3.36K
4
FTUS
Flow Traders U.S.
New York
+$365

Top Sellers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
-$57.2K
2
SOA
Sea Otter Advisors
Florida
-$17.1K
3
SFM
Spartan Fund Management
Canada
-$9.88K
4
EAM
Exos Asset Management
New York
-$2.88K
5
CCM
Condor Capital Management
New Jersey
-$1.41K
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
1
Highbridge Capital Management
New York
$92.9K – – –
PC
2
Periscope Capital
Ontario, Canada
$58.9K -$57.2K -418,400 -46%
PAMP
3
Polar Asset Management Partners
Ontario, Canada
$43.4K – – –
BFM
4
Boothbay Fund Management
New York
$37.5K – – –
JP Morgan Chase
5
JP Morgan Chase
New York
$33.3K – – –
ASM
6
ATW SPAC Management
New York
$31.1K – – –
SCM
7
Saba Capital Management
New York
$30.1K – – –
SCM
8
Shaolin Capital Management
Florida
$26.4K +$10.1K +73,867 +39%
RCM
9
Rivernorth Capital Management
Florida
$25K – – –
CAC
10
Cowen and Company
New York
$25K +$34.1K +249,855 New
CS
11
Clear Street
New York
$19.1K – – –
EAM
12
Exos Asset Management
New York
$18.1K -$2.88K -21,100 -11%
Walleye Capital
13
Walleye Capital
New York
$16.8K – – –
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$16.7K – – –
CH
15
CVI Holdings
Delaware
$15.6K – – –
WAM
16
Wolverine Asset Management
Illinois
$12.2K – – –
AA
17
AQR Arbitrage
Connecticut
$11.1K – – –
CC
18
Centiva Capital
New York
$11.1K – – –
Walleye Trading
19
Walleye Trading
New York
$9.46K – – –
MTCM
20
Mint Tower Capital Management
Netherlands
$8K – – –
SIA
21
Schechter Investment Advisors
Michigan
$4.6K -$137 -1,000 -2%
SIA
22
SkyView Investment Advisors
New Jersey
$4K – – –
Citadel Advisors
23
Citadel Advisors
Florida
$2.73K +$3.36K +24,583 New
GF
24
Gabelli Funds
New York
$2.71K – – –
GCIA
25
Gabelli & Co Investment Advisers
New York
$2.08K – – –
1
2

BLACR Hedge Fund Activity: Q2 2024 in Review

30 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Bellevue Life Sciences Acquisition Corp. Rights (BLACR) for Q2 2024, worth a combined $562K — down 30% from $798K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of BLACR and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.

The largest buyer was Cowen and Company, opening a new position worth an estimated $34.1K. The largest seller was Periscope Capital, cutting an estimated $57.2K.

  • 30 institutional investors held Bellevue Life Sciences Acquisition Corp. Rights (BLACR) as of Q2 2024, down from 31 in Q1 2024.
  • Funds reported $562K of Bellevue Life Sciences Acquisition Corp. Rights stock for Q2 2024, down 30% quarter-over-quarter.
  • 2 funds opened new Bellevue Life Sciences Acquisition Corp. Rights positions in Q2 2024 and 3 closed out, a net change of -1 holder.
  • The largest Bellevue Life Sciences Acquisition Corp. Rights buyer in Q2 2024 was Cowen and Company, an estimated $34.1K added.
  • The largest Bellevue Life Sciences Acquisition Corp. Rights seller in Q2 2024 was Periscope Capital, an estimated $57.2K sold.

Based on aggregated 13F filings for Q2 2024.